TN 13
Alternative Names: TN-13; TN-13 NK-SHIELDLatest Information Update: 04 Sep 2024
Price :
$50 *
At a glance
- Originator Ingenium Therapeutics
- Class Antineoplastics; Peptides
- Mechanism of Action Natural killer cell stimulants; P38 mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 29 Jul 2024 Ingenium Therapeutics has patents pending for'Composition for enhancing activity of natural killer cells'in Australia
- 29 Jul 2024 Preclinical trials in Solid tumours in South Korea (Parenteral) prior to July 2024 (Ingenium Therapeutics pipeline, July 2024)
- 29 Jul 2024 Pharmacodynamic data from preclinical studies in Solid tumours released by Ingenium Therapeutics (Ingenium Therapeutics pipeline, July 2024)